ARCHIVES

FDA Declares Taxol Orphan Drug For KS; Can IVAX Break Bristol’s Exclusivity?

This article is from The Cancer Letter archive.

Vol. 23 No. 32 | August 15, 1997

Download PDF Visit The Full Archive

Related Articles

In Brief: Top Priority: Keep Rauscher; Pay Raise Bill No Moving; Miller, Holland Head AACR, ASCO

May 21, 1976

In Congress: NCI Apologizes For Delay In Report On Radioactive Fallout

September 18, 1998

Taxol Recommended For Second Line Therapy In Platinum-Resistant Metastatic Ovarian Cancer

November 20, 1992

Grantees May Get More Freedom In Adjusting budgets

February 21, 1975

Block, Committee Agree; No New PDQ For General Public

January 11, 1985

DCCP Board Okays Concept Of Study On Black/White Survival Differences

March 5, 1982